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Add Health design 
The National Longitudinal Study of Adolescent to Adult Health (Add Health) is an ongoing, 
nationally-representative longitudinal study of the social, behavioral, and biological linkages in 
health and developmental trajectories from early adolescence into adulthood. The Add Health 
cohort was drawn from a probability sample of 132 middle and high schools and is representative 
of American adolescents in grades 7-12 in 1994-1995. The adolescent cohort has been followed 
for 20+ years with in-home interviews in 1995 (Wave I, 79% response rate), 1996 (Wave II, 89% 
response rate), 2001-02 (Wave III, 77% response rate), and 2008 (Wave IV, 80% response rate).  
Wave V is currently underway in 2016-2018 when respondents are aged 32-42.  The Add Health 
design included an embedded genetic sample of pairs of identical twins, fraternal twins, full sibs, 
half sibs, and adolescents who grew up in the same household but have no biological 
relationship. Add Health is a multiracial and multiethnic sample with substantial numbers of 
individuals with Hispanic and Asian ancestry.  For more information about the design of Add 
Health see Harris 2010 and Harris et al. 2013.   
 
Genome-wide Genotyping 
At Wave IV, Add Health collected Oragene saliva samples from consenting participants (96% of 
n=15,701), and requested a second consent to archive their samples for future genomic studies.  
Approximately 80% consented to archive and were thus eligible for genome-wide genotyping. 
Genotyping was completed over three years funded by R01 HD073342 (PI Harris) and R01 
HD060726 (PIs Harris, Boardman, and McQueen).  Add Health utilized two Illumina platforms for 
genotyping: the Illumina Human Omni1-Quad BeadChip for the majority of samples and the 
Illumina Human Omni-2.5 Quad BeadChip for the remainder. The two platforms utilized tag SNP 
technology to identify and include over 1.1 million and 2.5 million genetic markers respectively 
from Omni1 and Omni2.5 derived from the International HapMap Project and the most informative 
markers from the 1000 Genomes Project (1KGP). The genetic markers include known disease-
associated SNPs from multiple sources, ancestry-informative markers, sex chromosomes, and 
ABO blood typing markers. The platforms also included probes for the detection of copy number 
variation (CNV) covering all common CNV regions and more than 5,000 rare CNV regions. After 
quality control procedures (described below), genotype data were available for 9,974 individuals: 
n=7,917 from the Illumina HumanOmni1-Quad chip and for 2,057 individuals from the Illumina 
HumanOmni2.5-Quad chip (Figure 1). After filtering, the Add Health genotype GWAS data 
contained n=609,130 single-nucleotide polymorphisms (SNPs) common to both chips to enable 
joint imputation to the entire Add Health population (see below).  
 
Quality Control (QC) report for Illumina HumanOmni1-Quad. Below we describe our approach 
to participant- and SNP-level exclusions (Table 1). 
 
SNP Marker Set. Initially, 9,344 individuals (Add Health samples, duplicates, and HapMap 
controls) were genotyped by Illumina HumanOmni1-Quad with 1,140,419 markers each. A total of 
1,058,111 markers are annotated by Illumina annotation file HumanOmni1-Quad-v1-0_H (82,308 
markers excluded). The following markers were removed: 142,695 A/T or G/C markers due to 
alignment uncertainty; 1,985 markers that were triallelic or did not map to chromosome 1-22 or 
chromosome X. After these exclusions, 913,431 markers entered the first-pass marker level QC. 
Next, we removed markers with call rates < 90% (N=20,008) and minor allele frequency (MAF) < 
0.5% (N=33,333). After the first-pass marker level QC, 860,090 markers remained.  
  
Sample-level QC. Next we conducted sample level QC by removing 308 individuals with < 90% 
call rate. After this step, the total genotyping rate in the remaining 9,036 individuals reached 
0.995. We then converted IDs assigned during genotyping to Add Health ID or HapMap ID, 
dropping three individuals who could not be mapped (n=9,033 remained).  After excluding 106 
HapMap controls, a total of 8,927 Add Health samples (with duplicates) remained.  
 
HapMap controls concordance check. A total of 106 HapMap controls were genotyped together 
with the Add Health samples, 99 of which were HapMap sample NA12003 and 7 of which were 
HapMap sample NA18856. We then compared the strand of HapMap controls and the external 
HapMap sample, NA12003, and performed the concordance check using the 518,630 overlapping 
and bi-allelic markers. The mean genotype matching error was 0.0045 and the mean allele 
matching error was 0.0023. Out of 518,630 markers, 5600 (1%) had mismatch rate > 0.01.  
 
Duplicate Concordance. A total of 288 duplicate pairs were genotyped. Using PLINK to estimate 
IBD, 281 of the pairs had a PI_HAT >0.99. The seven pairs with PI_HAT<0.99 were dropped and 
the two plates on which these pairs resided were flagged for additional QC. For matching pairs, 
the genotyping instance with the highest call rate was retained. 
 
Sex check and heterozygosity check. We inferred genetic sex based on X chromosome 
heterozygosity as implemented in PLINK separately by self-reported race/ethnicity. Autosomal 
heterozygosity was also calculated and compared to X chromosome estimates. Using the 
heterozygosity estimate (F), genetic sex was defined to be female if F < 0.2 and male if F > 0.8 
(PLINK default); F values 0.2-0.8 indicated an ambiguous sex. A total of 94 genetic sex-
discordant samples were dropped and the plates on which the samples resided were flagged for 
additional QC. An additional 44 individuals with higher than expected autosomal heterozygosity or 
ambiguous X heterozygosity that may indicate a sex mismatch also were dropped; sex 
mismatches did not favor a particular direction, indicating that sample swaps, not contamination, 
was the likely problem (Table 2; Figure 2).  
 
Second-pass marker QC, HWE by ancestry. Marker level QC was repeated on the remaining 
individuals. Six markers were removed due to a call rate <90%; 120 markers were removed due 
to a MAF<0.5%; and 7,953 were removed due an ancestry specific Hardy-Weinberg Equilibrium 
P<5x10-5. Further we removed 4,375 variants that shows low concordance between duplicate 
pairs. 
 
Summary. The five preceding QC steps identified 55 plates with no evidence of sample switching 
through sex-mismatches or duplicate mismatch and 50 plates with evidence of at least one 
sample swap. Our strategy to identify participants with high certainty of sample identity on the 50 
plates with evidence of sample misidentification was performed in conjunction with the data 
genotyped on the Omni 2.5 and therefore follows our description of Omni 2.5 QC. 
 
QC report for Illumina HumanOmni2.5-Quad. Below we describe our approach to participant- 
and SNP-level exclusions (Table 1). 
 
SNP Marker Set. Initially, 2,461 individuals (Add Health samples, duplicates, and HapMap 
controls) were genotyped by Illumina HumanOmni2.5-Quad with 2,369,541 markers each. All 
markers were in the annotation file and none were removed due to alignment uncertainty. We 
then removed 9,328 markers not on chromosome 1-22 and chromosome X, leaving 2,360,213 
 markers entering the first-pass marker level QC. Further, for first pass QC, we removed markers 
with call rate < 90% (N=56,182) and MAF < 0.5% (N=571,200). After the first-pass marker level 
QC, 1,732,831 markers remained.  
 
Sample level QC. Next we conduct sample level QC by, first, removing 65 individuals with <90% 
call rate. After this step, the total genotyping rate in the remaining 2,396 individuals reached 
0.9941. Next, we converted IDs assigned during genotyping to Add Health ID or HapMap ID; eight 
individuals could not be mapped (n=2,391 individuals remaining).  Finally, after excluding the 30 
HapMap controls, a total of 2,361 Add Health samples (with duplicates) remained.  
 
HapMap controls concordance check. A total of 30 HapMap controls were genotyped together 
with the Add Health samples, all of which were from HapMap sample NA12003. For example, we 
compared the strand of HapMap controls and the external HapMap sample, NA12003, and 
performed the concordance check using the 468,501 overlapping and bi-allelic markers. Out of 
464,508 markers, 2,166 (0.5%) had mismatch rate > 0.01, with remaining markers’ mean 
mismatch rate =0.  
 
Duplicate Concordance. A total of 48 duplicate pairs were genotyped. Using PLINK to estimate 
IBD, all of the pairs had a PI_HAT >0.99.  
 
Sex check and heterozygosity check. We inferred genetic sex based on X chromosome 
heterozygosity, as implemented in PLINK, separately within each self-reported race/ethnicity. 
Autosomal heterozygosity was also calculated and compared to X chromosome estimates. 
Genetic sex was again defined to be female if F < 0.2 and male if F > 0.8 (PLINK default), with F 
values 0.2-0.8 indicative of ambiguous sex. Samples that were the opposite of self-reported sex 
(N=23) were dropped and plates on which these samples resided were flagged for additional QC. 
In addition, individuals with higher than expected autosomal heterozygosity, or ambiguous X 
heterozygosity that may indicate a sex mismatch (N=16) were also dropped.  Sex mismatches did 
not favor a particular direction, indicating sample swapping, rather than contamination as the likely 
problem (Table 2, Figure 2).  
 
Second-pass marker QC, HWE by ancestry. Marker level QC was repeated on the remaining 
individuals. One hundred ninety three markers were removed due to a call rate <90%; 6,508 
markers were removed due to a MAF<0.5%; and 4,607 were removed due an ancestry specific 
Hardy-Weinberg Equilibrium P<5x10-5. Further we removed 5,581 variants that shows low 
concordance between duplicate pairs. 
 
Summary. In total, the five preceding QC steps identified 13 plates with no evidence of sample 
switching through sex-mismatches or duplicate mismatch and 14 plates with evidence of at least 
one sample swap. Below we describe our strategy to identify participants with high certainty of 
sample identity on the 14 plates with evidence of sample misidentification. This was done in 
conjunction with the data genotyped on the Omni 1. 
 
Add Health Exome Chip data. Given the non-negligible proportion of plates with at least one 
potential instance of sample swapping, we performed a third round of QC by comparing all 
individuals genotyped on Omni 1 or 2.5 to previously performed Exome Chip genotyping, funded 
by R01 HD057194 (PIs: Gordon-Larsen and North).  Because the samples used for the exome 
genotyping were the first specimens selected from the Add Health DNA archive, they are 
considered to be of higher quality than those used for subsequent genotyping. (Consistent with 
 this expectation, QC of Exome Chip data indicated genotypes of high fidelity (e.g. >99% 
concordance in genetic vs. self-reported sex; 97% of participants with SNP missingness <3%).  
 
Exome Pairs. First, data from the Exome Chip and both Omni arrays were aligned and combined. 
Only markers well-genotyped on all three arrays were retained (n=2,961markers). A common 
dataset was then constructed, which included n= 20,150 individuals (with duplicates) and 
relatedness between these 20,150 individuals was calculated using PRIMUS4 
(https://primus.gs.washington.edu/primusweb/). Of the 8,662 expected pairs (i.e. individuals 
genotyped on the Exome Chip and one of the Omni arrays), 8,585 matched (99%). Although the 
majority individuals that did not match their Exome Chip genotype resided on plates already 
flagged for additional follow up, an additional 11 plates were identified as containing a mismatch 
and flagged for additional QC.  
 
Sample Retention. All samples that resided on any of the 67 plates without evidence of sample 
swaps were retained (n=5,539), as were all Omni 1 and 2.5 array individuals who matched their 
ExomeChip pair (n=4,164) (Figure 1). For individuals that were not genotyped on the Exome 
Chip, they were retained if they showed a relationship as expected by self-report (i.e. if A and B 
reported they were full siblings and they showed IBD estimates consistent with that relationship or 
a one degree further away relationship (i.e. half-sibs), we retained both individuals) (n=338) 
(Figure 3). In total, 10,041 samples were retained. 
 
Merging Omni1 and Omni2.5 arrays and imputation. After initial QC, we merged the two 
genotyped SNP data sets. There were a total of 1,954,448 markers on the two arrays, of which 
609,130 were common to both arrays and passed the above QC steps (call rate in merged data > 
80%). As strand files were not available, all palindromic (i.e. G/C or A/T) SNPs were dropped.  
Two imputation releases are provided: imputation of European ancestral participants using the 
HRC imputation panel and the GSCAN protocol (see below); and imputation of all (i.e. multiethnic) 
Add Health participants to the 1000 Genomes Phase 3 imputation panel using the GLGC/GIANT 
protocol (see below). No filtering was performed after imputation. 
 
Relatedness 
More precise relatedness was calculated in all remaining individuals using PRIMUS4 
(https://primus.gs.washington.edu/primusweb/). A set of 66 (n=10,041-66; 0.66%; 9,974 unique 
participants retained) participants appeared to be closely related to more individuals than is 
plausible. Because excessive “relatedness” can reflect genotyping error, these participants were 
removed from the genotype data. We also removed one unintentional duplicate. In the remaining 
9,974 participants, the genetic relatedness matrix (GRM) was calculated using PLINK’s --make-rel 
command. Among previously identified pairs, we genetically confirmed 143 monozygotic twin 
pairs, 185 dizygotic twin pairs, 499 full sibling pairs, and 158 half-sibling pairs. 
 
Population structure. To evaluate population structure, we calculated principal components in 
the unrelated subset in eigenstrat5. The remaining individuals and HapMap3 reference samples 
were projected into this space (Figure 4). These eigenvectors may be used as covariates in the 
statistical model used for association testing to adjust for possible population stratification.  
 Table 1. SNP- and sample-level exclusions yielding n=10,778* unique Add Health participants for second-pass QC. 
 Omni1 Omni 2.5 
Procedure N. markers 
N. 
individuals N. markers N. individuals 
Start 1,140,419 9,344 2,369,541 2,461 
Markers in the annotation file 1,058,111 9,344 na na 
Removing A/T G/C markers and markers with both alleles missing/alignment uncertainty 915,416 9,344 na na 
Removing triallelic markers and markers not on chromosomes 1-23 913,431 9,344 2,360,213 2,461 
Removing markers with call rate < 90% 893,423 9,344 2,304,031 2,461 
Removing markers with call rate MAF < 0.5% 860,090 9,344 1,732,831 2,461 
Removing individuals with call rate < 90% 860,090 9,036 1,732,831 2,396 
Updating EAID to AID 860,090 9,033 1,732,831 2,391 
Exclude HapMap controls 860,090 8,927 1,732,831 2,361 
Duplicate concordance check 860,090 8,645 1,732,831 2,314 
Sex check 860,090 8,551 1,732,831 2,291 
Het check + sex check 860,090 8,507 1,732,831 2,275 
2nd-pass call rate< 90% 860,084 8,507 1,732,638 2,275 
2nd-pass MAF 859,964 8,507 1,726,130 2,275 
HWE 852,011 8,508 1,721,523 2,275 
Poor duplicate concordance 847,636 8,508 1,715,942 2,275 
*Five Add Health participants were genotyped on both Omni 1 and Omni 2.5 chips, yielding a combined sample size of 10,783; n=10,778 unique 
participants. 




Table 2: Direction of Sex Mismatches. 
F < 0.2, female; F > 0.8, male 
  Omni1 Omni2.5 
  
Reported sex 
M; genetic sex 
F 
Reported sex 
F; genetic sex 
M 
Reported sex 
M; genetic sex 
F 
Reported sex 
F; genetic sex 
M 
White 40 40 1 5 
Black 6 6 NA NA 
Native American 0 0 0 0 
Asian 1 0 3 5 
Hispanic 1 0 6 4 
  
 Figure 1. Second-pass QC sample retention strategy. Of the initial 10,778 samples retained after 
SNP- and sample-level exclusions (Table 1), 5,539 samples were genotyped only on plates with 
no evidence of sex mismatches or duplicate errors. In order to maximize our sample size, we then 
performed third pass QC, which examined independently genotyped exome chip data and 
previously reported kinship. Using these independent sources, we retained a total of n=4,164 
whose Omni and Exome Chip data matched, n=338 participants that showed a biologically 
plausible relationship (within 1 degree of self-reported relationship) with another genotyped 
participant that passed QC (either Exome or Omni data).  After these QC steps, we identified a 










Figure 3. Allele sharing color coded by self-reported relationship
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 Add Health Haplotype Reference Consortium (HRC) Imputation Protocol 
 
Summary: Europeans in the final release of the Add Health genotyped data were imputed with 
Release 1 of the Haplotype Reference Consortium reference panel (HRCr1.1).1 The HRC panel 
currently provides the most comprehensive imputation panel for European ancestry. Amongst 
other uses, HRC imputed data may commonly be used both for genome-wide association studies 
or for the construction of polygenic scores using imputed (rather than genotyped) data. For 
imputation of non-European samples, the 1000 Genomes Phase 3 reference panel2 is currently 
more appropriate.  
 
SNP-Level Filters: Before imputation, some SNP-level filters were applied. Of 606,673 variants in 
the final Add Health genotyped data, 13,721 were removed with a per-variant missing call rate 
filter of 0.02; 245,589 were removed with a Hardy-Weinberg Equilibrium filter of 0.0001, and 609 
were removed with a minor allele frequency filter of 0.01, leaving 346,754 SNPs carried through to 
imputation. 
 
Individual-Level Filters: Some individual-level filters were also applied. First, the sample was 
reduced to only individuals of genetically-determined European ethnicity. European ethnicity was 
ascertained through the protocol developed for the common variant association analysis of the 
GWAS & Sequencing Consortium of Alcohol and Nicotine use (GSCAN). 
 
The GSCAN website is available here: http://gscan.sph.umich.edu, and the ethnicity protocol can 




 Results of that Principal-Components based analysis are plotted here:
 
 
In total, of 9,974 individuals in the final Add Health genotyped data, 4,187 non-European 
individuals were dropped.  
 
Next, individuals with high rates of genotyping failures were removed with a per-sample missing 
call rate of 0.05. In total, of 9,974 individuals in the final Add Health genotyped data, 40 non- 
individuals were dropped. 
 
Finally, individuals with excessively high or low rates of heterozygosity were removed by dropping 
those with an F-statistic lower than -0.3 or higher than 0.3. In total, of 9,974 individuals in the final 
Add Health genotyped data, 58 individuals were dropped.  
 
Ancestral outliers were screened for using the Plink Identity-By-State (IBS) binomial test with a 
threshold of 0.05, though no outliers were identified. 
 
In summary, 5,690 individuals were carried through to imputation.  
 
 Imputation: Imputation was performed with the Michigan Imputation Server3, using the HRC r1.1 
2016 reference panel and ShapeIt v2.r790 phasing software. Options were specified for a 
European (“EUR”) population and for “Quality Control & Imputation” mode. 
 
The free Michigan Imputation Server is available here: 
https://imputationserver.sph.umich.edu/index.html. 
 
Imputation was completed and imputed .vcf files downloaded on July 25, 2017; imputation 
execution time lasted 38 hours, 40 minutes, and 19 seconds. All imputation procedures were 
conducted by Robbee Wedow, University of Colorado Boulder.  
  
 Add Health 1KG phase 3 Imputation Protocol 
 
Summary: As described above, 1000 Genomes imputation is more appropriate for non-European 
samples. Thus, Add Health investigators used the Global Lipids Genetics/GIANT Consortium 
Imputation and Analysis Plan, version 2 (updated March 17th, 2017) to guide imputation to the 
1000 Genomes reference panel. Imputation was performed on the University of Michigan 
imputation server (https://imputationserver.sph.umich.edu) All n=9,974 Add Health participants 
were imputed using this analysis plan.  
 
There were two major components to this analysis plan:  
1) Genome-wide genotypes must be on the correct build (37/hg19) and correct strand 
(forward).  
2) Imputation of genotypes is performed using the 1KG phase 3 
 
Standard pre-imputation QC criteria were applied:  
• Sample call rate (cut off >95% threshold recommended)  
• Exclude samples with heterozygosity > median + 3*IQR  
• Remove gender mismatches 
• Remove duplicates  
• Remove PCA outliers using a PCA projection of the study samples onto 1KG reference 
samples.  
• Hardy-Weinberg p>10-6, SNP call rate ≥98% 
• Remove monomorphic markers 
 
Prepare files for imputation  
The “HRC/1KG Imputation Preparation and Checking Tool” developed by Will Rayner was used to 
check input data for accuracy relative to expected HRC or 1000G inputs prior to imputation. This 
process was used to identify errors in input data, including incorrect REF/ALT designations, 
incorrect strand designations, extreme deviations from expected allele frequencies, and 
palindromic (A/T and G/C) SNPs with allele frequency near 0.5 that are often the source of 
imputation errors, and generates commands to make files that have fixed or removed these 
problematic variants. The tool can be downloaded here: 
http://www.well.ox.ac.uk/~wrayner/tools/HRC-1000G-check-bim.v4.2.5.zip 
Impute to 1KG phase 3 panel  
The 1KG phase 3 samples has both European and non-European samples and includes SNPs, 
indels, and CNVs.  
 
The following options at the Michigan Imputation Server were used: 
• Reference Panel: 1000G Phase3 v5 
• Phasing: Eagle v2.3 
• Population: as appropriate for the study (used only for quality control purposes)  
• Mode: Quality Control & Imputation 
Note: Chromosome X will need to be imputed separate from other chromosomes after 
reformatting plink code 23 to X in the VCF file. Currently, SHAPEIT is the only available method 
for phasing chrX.  
  
Imputation was completed and imputed .vcf files downloaded in November 2017. All imputation 
procedures were conducted by Robbee Wedow, University of Colorado Boulder.   
 
Send questions to addhealth_genetics@unc.edu. 
 




















1. McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat. 
Genet. 48, (2016). 
2. Auton, A. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015). 
3. Das, S. et al. Next-generation genotype imputation service and methods. Nat. Genet. 48, 
1284–1287 (2016). 
 
 
 
 
 
